Are QSAR models available for all endpoints?

QSAR models are available and in use for some endpoints, while being limited for others (e.g. long term mammalian toxicity).  There are several reasons, including:

  1. the limited amount of high quality experimental data currently available (and released by industry) for some endpoints,
  2. the higher complexity of the chemical and biological processes involved in generating the toxicity for some endpoints, and
  3. the lower regulatory acceptance for certain endpoints.  

In general, for physico-chemical properties QSAR models are more reliable, because the phenomenon to be modelled is less complex, and thousands of experimental results are available in the databases.  Whereas, for models to predict chronic effects, the data are much more limited, and the phenomenon is much more complex.

The EC funded ANTARES project is evaluating existing models which could be used for REACH.  Hundreds of possible models have been identified and listed, which theoretically could be used for tens of REACH endpoints. ANTARES is currently checking the performance of the QSAR models for several endpoints.  (See: FAQs: ‘Is there an independent review of QSAR models’ and ‘What makes a good QSAR model’.)

Related FAQ

What's next